Dr. William Greene, CIO of the Hevolution Foundation, joins The 966 to talk latest investments, strategy for Hevolution

The 966

Content provided by The 966 Podcast and The 966. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The 966 Podcast and The 966 or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

1+ y ago 30:44

MP3•Episode home

William Greene, MD, Chief Investment Officer (CIO) of the Hevolution Foundation, joins The 966 to talk about Hevolution's investment strategy and role as an investor in the emerging field of Healthspan Science. As CIO, Dr. Greene oversees all aspects of Hevolution Foundation’s investment strategy, planning, analysis, and execution.

The Hevolution Foundation, based in Riyadh, is a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science.

Last month, Hevolution announced its first ever impact investment to catalyze the healthspan and geroscience ecosystem and drive transformative breakthroughs in healthy aging.

Dr. William Greene’s leadership positions have included founder, biotechnology executive, investor, and clinician. As CEO, he built Iconic Therapeutics through discovery, clinical development and venture financing, leading to a successful sale of the company. He later helmed longevity biotech company Fountain Therapeutics and co-founded digital therapeutics startup Pear Therapeutics.

Dr. Greene spent 12 years at MPM Capital where he was a Managing Director and member of its Investment Committee, responsible for biotechnology and medical technology investments worldwide. He was also founding Chairman and head of the Investment Committee at the Global Health Investment Fund, a groundbreaking impact-oriented venture fund in collaboration with the Gates Foundation, which successfully scaled both investment returns and health impact simultaneously.

Earlier in his career, Dr. Greene was an Assistant Professor of Medicine at University of California at San Francisco (UCSF) and led clinical trials and strategy for a variety of therapeutic areas at Genentech.

Dr. Greene earned his BA from Wesleyan University and his MD from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale and a Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health (NIH).

135 episodes

#News Talk #Business #News #Saudi U.S.-Trade Group, Inc #Lucien Zeigler #Richard Wilson #Saudi Arabia #Oil #Energy #Middle East #Investing